Evidence map›Paper›PMID 41527205›Full record

ArticleGM crops & food2026

From lab to market: industrialization barriers and regulation optimization for new breeding technologies in China.

Yu Qin, Kezhen Su

Abstract read
In one paragraph

Article in GM crops & food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yu QinKoguan School of Law, Shanghai Jiao Tong University, Shanghai, China.
Kezhen SuSchool of Law, Fuzhou University, Fuzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New Breeding Technologies (NBTs), particularly gene editing, are reshaping the global competitive landscape of the seed industry and providing technological support for ensuring food security and advancing the green transformation of agriculture. This study aims to assess China's distinctive position within the global regulatory spectrum of NBTs, an intermediary status between the European Union's process-based model and the product-based model adopted by countries such as the United States and Argentina. Building on this, the article constructs an institutional analysis framework centered on the agricultural industry chain, encompassing four critical stages: research and development collaboration; biosafety assessment and administrative licensing; intellectual property and plant breeders' rights protection; and consumer perception and labeling governance. Through comparative legal analysis and an examination of the entire chain, the study systematically reveals the institutional challenges confronting China's commercialization of NBTs. These challenges include: weak mechanisms for linking the interests of industry, academia, and research institutions; path dependence on approval procedures rooted in traditional genetic modification logic; plant variety protection and relief mechanisms that fail to respond promptly to the technical attributes of NBTs; and consumer distrust driven by the interplay between qualitative labeling and risk narratives. In response, four key areas of reform are proposed: strengthening benefit-sharing and collaborative innovation mechanisms; introducing differentiated, risk-proportionate review pathways for low-risk gene-edited crops; improving breeders' rights and substantive derived variety rules, complemented by punitive damages and insurance mechanisms; and reforming risk communication and labeling systems by adopting quantitative thresholds and tiered information disclosure as the core principles.

Indexed as

Crops, AgriculturalPlant BreedingAgricultureChinaGene EditingPlants, Genetically ModifiedGene editinggene modificationindustrializationinstitutional mechanismnew breeding technologies (NBTs)

Identifiers

PMID41527205
PMCPMC12803001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.